Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis

References

• Malm D, Riise Stensland HM, Edvardsen Ø, et al. The natural course and complications of alpha-mannosidosis–a retrospective and descriptive study. J Inher Metab Dis. 2014;37(1):1–10. doi: 10.1007/s10545-013-9622-2.
   PubMed Web of Science ®Google Scholar
• Paciotti S, Codini M, Tasegian A, et al. Lysosomal alpha-mannosidase and alpha-mannosidosis. Front Biosci. 2017;22(1):157–167. doi: 10.2741/4478.
   Google Scholar
• Borgwardt L, Lund AM, Dali CI. Alpha-mannosidosis – a review of genetic, clinical findings and options of treatment. Pediatr Endocrinol Rev. 2014;12 Suppl 1(Suppl 1):185–191.
   PubMedGoogle Scholar
• Ceccarini MR, Codini M, Conte C, et al. Alpha-mannosidosis: therapeutic strategies. Int J Mol Sci. 2018;19(5):1500. doi: 10.3390/ijms19051500.
   PubMed Web of Science ®Google Scholar
• Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215–1223. doi: 10.1007/s10545-018-0185-0.
   PubMed Web of Science ®Google Scholar
• Lund AM, Borgwardt L, Cattaneo F, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225–1233. doi: 10.1007/s10545-018-0175-2.
   PubMed Web of Science ®Google Scholar
• Guffon N, Konstantopoulou V, Hennermann JB, et al. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: a phase 2, open label, multicenter study. J Inherit Metab Dis. 2023;46(4):705–719. doi: 10.1002/jimd.12602.
   PubMed Web of Science ®Google Scholar
• Velmanase Alfa-Tycv V. Am J Health Syst Pharm. 2023;80(13):796–798. doi: 10.1093/ajhp/zxad074.
   PubMedGoogle Scholar
• Schreiber-Katz O, Klug C, Thiele S, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9(1):210. doi: 10.1186/s13023-014-0210-9.
   PubMedGoogle Scholar
• Winquist E, Bell CM, Clarke JT, et al. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15(6):982–986. doi: 10.1016/j.jval.2012.06.009.
   PubMed Web of Science ®Google Scholar
• Karnon J, Haji Ali Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics. 2014;32(6):547–558. doi: 10.1007/s40273-014-0147-9.
   PubMed Web of Science ®Google Scholar
• Gutić M, Milosavljević MN, Janković SM. Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C. Int J Clin Pharm. 2022;44(6):1442–1453. doi: 10.1007/s11096-022-01491-8.
   PubMed Web of Science ®Google Scholar
• Gutić M, Milosavljević MN, Safiye T, et al. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):561–570. doi: 10.1080/14737167.2023.2197213.
   PubMed Web of Science ®Google Scholar
• Lipiński P, Różdżyńska-Świątkowska A, Iwanicka-Pronicka K, et al. Long-term outcome of patients with alpha-mannosidosis – A single center study. Mol Genet Metab Rep. 2022;30:100826. doi: 10.1016/j.ymgmr.2021.100826.
   PubMed Web of Science ®Google Scholar
• Hennermann JB, Raebel EM, Donà F, et al. Mortality in patients with alpha-mannosidosis: a review of patients’ data and the literature. Orphanet J Rare Dis. 2022;17(1):287. doi: 10.1186/s13023-022-02422-6.
   PubMed Web of Science ®Google Scholar
• Borgwardt L, Lund AM, Amraoui Y, et al. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis. Mol Genet Metab. 2017;120(1–2):s30. doi: 10.1016/j.ymgme.2016.11.048.
   Web of Science ®Google Scholar
• Naumchik BM, Gupta A, Flanagan-Steet H, et al. The role of hematopoietic cell transplant in the glycoprotein diseases. Cells. 2020;9(6):1411. doi: 10.3390/cells9061411.
   PubMed Web of Science ®Google Scholar
• Tordrup D, Smith R, Kamenov K, et al. Global return on investment and cost-effectiveness of WHO’s HEAR interventions for hearing loss: a modelling study. Lancet Glob Health. 2022;10(1):e52–e62. doi: 10.1016/S2214-109X(21)00447-2.
   PubMed Web of Science ®Google Scholar
• Rulebook on the maximum amount of reimbursements for medical and technical aids that are issued at the expense of mandatory health insurance funds. Official Gazette of the Republic of Serbia No. 134/2022-44, 16/2023-9, 25/2023-95, 47/2023-12.
   Google Scholar
• McDaid D, Park AL, Chadha S. Estimating the global costs of hearing loss. Int J Audiol. 2021;60(3):162–170. doi: 10.1080/14992027.2021.1883197.
   PubMed Web of Science ®Google Scholar
• Fattori A, Neri L, Aguglia E, et al. Estimating the impact of workplace bullying: humanistic and economic burden among workers with chronic medical conditions. Biomed Res Int. 2015;2015:708908–708912. doi: 10.1155/2015/708908.
   PubMed Web of Science ®Google Scholar
• Shahat ARS, Greco G. The economic costs of childhood disability: a literature review. Int J Environ Res Public Health. 2021;18(7):3531. doi: 10.3390/ijerph18073531.
   PubMed Web of Science ®Google Scholar
• Chittrakul J, Siviroj P, Sungkarat S, et al. Multi-System physical exercise intervention for fall prevention and quality of life in pre-frail older adults: a randomized controlled trial. Int J Environ Res Public Health. 2020;17(9):3102. doi: 10.3390/ijerph17093102.
   PubMed Web of Science ®Google Scholar
• Davis JC, Dian L, Khan KM, et al. Cognitive status is a determinant of health resource utilization among individuals with a history of falls: a 12-month prospective cohort study. Osteoporos Int. 2016;27(3):943–951. doi: 10.1007/s00198-015-3350-4.
   PubMed Web of Science ®Google Scholar
• Marciano RC, Cardoso MGF, Vasconcelos MA, et al. Behavioral disorders and impairment of quality of life in children and adolescents with lower urinary tract dysfunction. J Pediatr Urol. 2018;14(6):568.e1–568.e7. doi: 10.1016/j.jpurol.2018.07.017.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs. 2012;26(7):581–600. PMID: 22712698. doi: 10.2165/11633900-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med. 2008;25(5):618–624. doi: 10.1111/j.1464-5491.2008.02430.x.
   PubMed Web of Science ®Google Scholar
• Marques AP, Ramke J, Cairns J, et al. The economics of vision impairment and its leading causes: a systematic review. EClinicalMedicine. 2022;46:101354. doi: 10.1016/j.eclinm.2022.101354.
   PubMedGoogle Scholar
• Lam CS, Dhedli PK, Russell S, et al. Cost-effectiveness of laparoscopic and open pediatric inguinal hernia repair. J Laparoendosc Adv Surg Tech A. 2022;32(7):805–810. doi: 10.1089/lap.2021.0800.
   PubMed Web of Science ®Google Scholar
• Clarke AE, Goldstein MK, Michelson D, et al. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res. 1997;6(2):169–184. doi: 10.1023/a:1026446302100.
   PubMed Web of Science ®Google Scholar
• Guest JF, Ingram A, Ayoub N, et al. Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom. PLOS One. 2018;13(2):e0191945. doi: 10.1371/journal.pone.0191945.
   PubMed Web of Science ®Google Scholar
• Shaikh N, Dando EE, Dunleavy ML, et al. A cost-utility analysis of 5 strategies for the management of acute otitis media in children. J Pediatr. 2017;189:54–60.e3. doi: 10.1016/j.jpeds.2017.05.047.
   PubMed Web of Science ®Google Scholar
• Wolleswinkel-van den Bosch JH, Stolk EA, Francois M, et al. The health care burden and societal impact of acute otitis media in seven European countries: results of an internet survey. Vaccine. 2010;28 Suppl 6(Suppl 6):G39–G52. doi: 10.1016/j.vaccine.2010.06.014.
   PubMedGoogle Scholar
• Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113(4):300–307. doi: 10.1016/s0002-9343(02)01222-6.
   PubMed Web of Science ®Google Scholar
• Adzić T, Rosić I, Jovanović D, et al. [Economic aspects of hospitaly treated pneumococcal pneumonia and the results of pneumo 23 vaccine use in Serbia]. Srp Arh Celok Lek. 2008;136(11–12):625–628. doi: 10.2298/sarh0812625a.
   PubMed Web of Science ®Google Scholar
• Dissemination database search. Statistical Office of The Republic of Serbia [cited 2023 Mar 17]. Available from: https://data.stat.gov.rs/Home/Result/09020101?languageCode=sr-Latn
   Google Scholar
• National Bank of the Republic of Serbia. Reference interest rate of the National Bank of the Republic of Serbia in 2023 [cited 2023 May 10]. Available from: https://nbs.rs/sr/ciljevi-i-funkcije/monetarna-politika/kamatne-stope/
   Google Scholar
• Rulebook on the prices of health services at the secondary and tertiary level of health care. Official Gazette of the Republic of Serbia No. 88/2021-34, 97/2021-250, 109/2021-93, 132/2021-132, 47/2022-258, 82/2022-11, 123/2022-10, 128/2022-56, 1/2023-7.
   Google Scholar
• Decision on the highest prices of drugs for use in human medicine, which are subject to prescription. Official Gazette of the Republic of Serbia No. 48/2021-8, 90/2021-3, 92/2021-12 (corr), 125/2021-42, 18/2022-65, 67/2022-75, 107/2022-8, 141/2022-178, 39/2023-25.
   Google Scholar
• Regulation on the criteria for the formation of the prices of drugs for use in human medicine, the mode of issuing of which is by prescription. Official Gazette of the Republic of Serbia No. 86/2015-15, 8/2016-9, 14/2018-36, 18/2019-27, 48/2021-7.
   Google Scholar
• Rulebook on the approved list of medicines prescribed and dispensed under compulsory health insurance scheme. Official Gazette of the Republic of Serbia No. 40/2022-185, 144/2022-148, 40/2023-168.
   Google Scholar
• Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in health technology assessment in eight European countries. Rare Dis Orphan Drugs. 2014;1(3):83–97.
   Google Scholar
• Katsigianni EI, Petrou P. A systematic review of economic evaluations of enzyme replacement therapy in lysosomal storage diseases. Cost Eff Resour Alloc. 2022;20(1):51. doi: 10.1186/s12962-022-00369-w.
   PubMed Web of Science ®Google Scholar
• Kanters TA, van der Ploeg AT, Kruijshaar ME, et al. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet J Rare Dis. 2017;12(1):179. doi: 10.1186/s13023-017-0731-0.
   PubMedGoogle Scholar
• Potter JE, Petts G, Ghosh A, et al. Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease. Orphanet J Rare Dis. 2021;16(1):235. doi: 10.1186/s13023-021-01849-7.
   PubMed Web of Science ®Google Scholar
• Aboobacker FN, Kulkarni UP, Korula A, et al. Hematopoietic stem cell transplantation is a cost-effective alternative to enzyme replacement therapy in Gaucher disease. Blood Cell Ther. 2022;5(3):69–74. doi: 10.31547/bct-2021-020.
   PubMedGoogle Scholar
• Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7(1):74. doi: 10.1186/1750-1172-7-74.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829–836. doi: 10.1093/qjmed/hci128.
   PubMed Web of Science ®Google Scholar